JPRN-UMIN000005598招募中3 期
Trial of novel combined therapy between interferon and hyperlipidemia for chronic hepatitis C patients - Novel combined therapy for chronic hepatitis C patients
Kyoto University Graduate School of Medicine Center for Genomic Medicine0 个研究点目标入组 100 人开始时间: 2011年5月13日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Combination therapy using pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C virus (HCV) infection 3 to 120 months after liver transplantatioHepatitis C reinfection after liver transplantationInfections and InfestationsChronic viral hepatitisISRCTN51477478Hannover Medical School (Medizinische Hochschule Hannover) (Germany)75
招募中
不适用
Combination therapy of interferon-alpha and interleukin-2 for patients with metastatic renal cell carcinoma after failure of targeted therapy because of adverse eventsJPRN-UMIN000017717Department of Urology, The University of Tokyo Hospital30
进行中（未招募）
不适用
COMBINED THERAPY WITH PEG-INTERFERON-a, RIBAVIRIN AND RITUXIMAB OF HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA - NDpatients anti-HCV, HCV RNA positivity, Na?ve, with cryoglobulinemic vasculitis (detection of serum cryoglobulins associated with purpura, arthralgias and weakness)and with chronic hepatitisMedDRA version: 9.1Level: SOCClassification code 10005329EUCTR2010-020659-30-ITAZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
进行中（未招募）
1 期
The purpose of this study is to evaluate how effective, safe and tolerable Sofosbuvir (SOF)/Velpatasvir(VEL) is when taken by people with recent hepatitis C virus (HCV) infection, in particular whether the length of treatment can be shortened. Study participants will be randomly (occur by chance) assigned into one of the two different groups. The short treatment duration group will receive SOF/VEL for 6 weeks and the standard treatment duration group will receive SOF/VEL for 12 weeks.Recent hepatitis C virus infection all genotypes.MedDRA version: 20.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-004243-39-NLniversity of New South Wales Australia250
进行中（未招募）
1 期
A study to evaluate how effective, safe and tolerable Sofosbuvir/Velpatasvir is when taken by people with recent hepatitis C virus infection, in particular whether the length of treatment can be shortened.Recent hepatitis C virus infection all genotypes.MedDRA version: 20.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-004243-39-GBThe University of New South Wales Australia250